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Abstract The Q-carboxyglutamic acid (Gla) content of several
variants of human prothrombin has been measured by using
capillary electrophoresis and laser-induced fluorescence (CE-
LIF). Both plasma-derived prothrombin and recombinant pro-
thrombin contain ten residues of Gla per molecule of protein. In
contrast, a variant of human prothrombin (containing the second
kringle domain of bovine prothrombin) was separated into two
populations that differed in their Gla content. Direct measure-
ment of the Gla content showed an association with the presence
or absence of the calcium-dependent conformational change that
is required for prothombinase function. Thus, the CE-LIF assay
is useful in determining the carboxylation status of recombinant
proteins.
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1. Introduction
Gamma-carboxyglutamic (Gla) acid is a naturally occurring
amino acid that is formed by the post-translational modi¢ca-
tion of glutamic acid during protein synthesis. Gla residues
are found predominantly in blood proteins (coagulation fac-
tors II, VII, IX, X, XI, XII, proteins C, S, and Z) [1] and in
bone and calci¢ed tissue (bone Gla protein or osteocalcin and
bone matrix protein) [2]. For plasma proteins, the conversion
of Glu to Gla is a post-translational step that involves a
vitamin K-dependent pathway in the rough endoplasmic re-
ticulum of hepatocytes (see [3] for a recent review). The pres-
ence of Gla residues imparts unique calcium-binding proper-
ties to a protein due to the extra carboxyl group in this
residue. In prothrombin, ten Gla residues in the amino-termi-
nal region (termed the Gla domain) bind calcium leading to a
calcium-dependent conformational change of the protein [1].
This conformational change is absolutely required for inter-
action with phospholipid membrane surfaces during pro-
thrombin activation in the prothrombinase complex.
Several previous studies have reported the qualitative and
quantitative determination of Gla in proteins. Typically, the
assays involve the hydrolysis of the protein to free amino
acids followed by derivatization, separation and quanti¢ca-
tion. A variety of reagents and methodologies have been de-
veloped including chemical modi¢cation [4], ion exchange
chromatography and analysis on an amino acid analyzer
[5^7], detection of an N-isobutyloxycarbonyl trimethyl ester
derivative by gas-liquid chromatography [8], speci¢c tritium
labeling or tritium exchange of Gla in protein or free Gla
followed by HPLC or mass spectrometry [9^11], and deriva-
tization with phenylisothiocyanate followed by reverse-phase
HPLC [12]. Recently, capillary electrophoresis was used to
compare quantitatively the di¡erences in Gla content in small
peptides [13]. Currently, the favored method [14,15] involves
hydrolysis of the protein with base followed by a pre-column
derivatization with o-phthalaldehyde and anion exchange
HPLC. This method yields the most consistent result for the
quanti¢cation of Gla by calculating the relative ratio of the
peak areas of Glu to Gla in a protein and using Asp as an
internal standard.
Recently, we developed a new method for the analysis of
Gla in proteins by labeling a base hydrolysate with £uorescein
isothiocyanate (FITC) followed by separation and detection
by capillary electrophoresis and laser-induced £uorescence
(CE-LIF) [16]. In this paper, we have used the assay to de-
termine the Gla content in several recombinant prothrombin
variants expressed in baby hamster kidney cells. The Gla con-
tents have then been correlated with the physical and biolog-
ical properties of these prothrombin variants.
2. Materials and methods
2.1. Materials
Electrophoresis reagent grade Tris, FITC isomer I (98%), and the
amino acid standards L-aspartic acid, L-glutamic acid, and L-Q-
carboxyglutamic acid were purchased from Sigma-Aldrich Canada
Ltd., Mississauga, Ont., Canada. HPLC grade acetone and perchloric
acid (69^72%), and capillary tubes (open ends, 1.5-1.8-100 mm, KI-
MAX-51) were from Fisher Scienti¢c Canada, Nepean, Ont., Canada.
Human plasma prothrombin was purchased from Haematologic
Technologies Inc., Essex Junction, VT, USA. A sample of recombi-
nant ferric iron-binding protein from Neisseria gonnhoreae was pre-
pared in this laboratory using a published procedure [17]. A poly-
clonal anti-human prothrombin antibody was purchased from
A⁄nity Biologicals, Hamilton, Ont., Canada. All other chemicals
were reagent grade or better, and were obtained from either Fisher
Scienti¢c Canada or Sigma-Aldrich Canada Ltd.
2.2. Instrumentation
All oligodeoxyribonucleotides in this study were synthesized on an
Applied Biosystems Model 391 DNA Synthesizer, using chemicals
supplied by Perkin Elmer (Applied Biosystems Division), Foster
City, CA, USA. Capillary electrophoresis was performed on a Beck-
man P/ACE 5000 automated CE-LIF system, manufactured by Beck-
man Instruments Inc., Palo Alto, CA, USA. Uncoated fused-silica
capillaries (Polymicro Technologies, Phoenix, AZ, USA) with an inner
diameter of 75 Wm, an outer diameter of 360 Wm, and a length of 57
cm were used. The detection system utilized an argon laser (4 mW)
and a £uorescence detector that were also manufactured by Beckman
Instruments Inc. Calcium-binding and phospholipid-binding proper-
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ties of proteins were measured by using a Perkin Elmer Luminescence
Spectrometer Model LS 50 obtained from the Perkin Elmer Corpo-
ration, Norwalk, CT, USA.
2.3. Plasmid construction
The expression of recombinant human prothrombin (rhFII) using
the pNUT-baby hamster kidney (BHK) cell system has been described
previously [18]. A mutant form of human prothrombin cDNA [19]
was prepared in which the coding region for the second cringle do-
main (Cys-170^Cys-248) was replaced with the equivalent region of
bovine prothrombin cDNA [20] by using PCR-directed mutagenesis.
Oligo 1 (5P-ATCGAATTCTCTTCTGTGTCCCGGACCGCGGCC-
GG-3P) and Oligo 2 (5P-ATCGAATTCTCTTCTCACAGTAGTT-
CAGGTCACAATA-3P) were used to amplify the kringle 2 region
of bovine prothrombin cDNA; the PCR introduced EarI sites at
the ends of the ampli¢ed fragment. Oligo 3 (5P-ATCGAATTCTCTT-
CACACACTGCTCCAATGGAGG-3P) and Oligo 4 (5P-ATCGAA-
TTCTCTTCTGTGAGGAGGCCGTGGAGGA-3P) were then used
to amplify the human prothrombin cDNA regions £anking the kringle
2 domain; the PCR procedure also introduced EarI sites that corre-
spond to those sites introduced by the bovine PCR ampli¢cation. The
human and bovine prothrombin PCR products were then cleaved with
Ear1, SstI and XbaI, and ligated into the SstI and XbaI sites of Blue-
script to reconstruct the human prothrombin cDNA now containing
the bovine kringle 2 sequence. The nucleotide sequences of all junc-
tions were then determined to ensure that no PCR errors had been
introduced during the PCR steps, and to ensure the correct orienta-
tion of fragments after the ligation step. The mutated cDNA was then
ligated into the pNUT expression vector.
2.4. Protein expression and puri¢cation
The mutated prothrombin expression vector was introduced into
BHK cells by using the calcium phosphate co-precipitation method
followed by selection with methotrexate [18]. Individual colonies were
picked, and cloned by plating to limiting dilution. The cloned cell lines
were expanded and analyzed for recombinant protein expression by
Western blotting using an anti-human prothrombin antibody. The
highest expressing cell line was used for further analysis. For large
scale production of recombinant protein, cells were grown in roller
bottles using DMEM-F12 medium (GIBCO-BRL, Life Technologies,
Burlington, Ont., Canada) containing ITS-K supplement (bovine pan-
creatic insulin at a ¢nal concentration of 10 mg/l, human apo-trans-
ferrin at 5.5 mg/l, sodium selenite at 6.7 Wg/l (all from Sigma-Aldrich),
ethanolamine (ICN Biochemicals, OH, USA) at 2 mg/l, AlbuMAX
(Life Technologies) at 0.5 g/l, and vitamin K1 (Abbott Laboratories,
Montreal, Que., Canada) at 10 Wg/l). The medium containing re-
combinant protein was harvested every 48 h, and stored at 4‡C in
10 mM benzamidine until further puri¢cation. The puri¢cation of the
recombinant protein was carried out essentially as described previ-
ously for recombinant human prothrombin [18], and consisted of
precipitation with barium citrate, anion exchange chromatography
by Fast Performance Liquid Chromatography (FPLC) using a column
of high Q resin (Pharmacia Biotech, Baie D’UrfeŁ, Que., Canada), and
pseudo-a⁄nity FPLC using a calcium gradient on a column of Mono-
Q HR 5/5 (Pharmacia Biotech); the last step was used to resolve the
di¡erent Gla-containing protein species [21].
2.5. Protein hydrolysis and Gla analysis
The protein sample (1 Wg of a 1 mg/ml solution in 20 mM Tris-HCl
bu¡er, pH 7.5 containing 150 mM NaCl) was added to 30 Wl of 2.5 M
KOH for alkaline hydrolysis, or 30 Wl of 6 N HCl for acid hydrolysis.
The mixture was transferred into a 1.5U100 mm capillary tube and
heat-sealed at both ends such that the air space was minimal. The
tubes were then submerged completely in the wells of a heating block
¢lled with industrial oil, and the hydrolysis was carried out at 110‡C
for 16 h. After hydrolysis, the sample was transferred to an Eppendorf
tube and silicate byproducts were removed by centrifugation at
13 000Ug for 5 min.
Prior to derivatization, the alkaline hydrolysate was neutralized by
the addition of 7% perchloric acid. After neutralization, the mixture
was left on ice for 15 min. and the insoluble potassium perchlorate
was removed by centrifugation at 13 000Ug for 10 min. at room
temperature. The supernatant (16 Wl) was transferred to a new Ep-
pendorf tube containing 12 Wl 0.2 M sodium bicarbonate bu¡er, pH
9.0, and 2 Wl of 50 mM £uorescein isothiocyanate (FITC) in aceto-
ne:pyridine (80:20, v:v) was added. The derivatization reaction was
carried out in the dark at room temperature for 24 h. The mixture was
diluted 400-fold with distilled water prior to CE.
The £uorescein thiocarbamyl (FTC) derivatives of the amino acids
were separated by using an automated CE system. Before each sepa-
ration, the capillary was rinsed with 0.1 M NaOH for 2 min followed
by a 4 min rinse with separation bu¡er (100 mM Tris-HCl, pH 8.25).
The sample was introduced by a 3 s low pressure injection (0.5 psi)
and the separation was carried out for 20 min at 30 kV and 25‡C. An
argon ion laser was used for detection; excitation was at 488 nm and
the emission was monitored at 520 þ 20 nm with a £uorescence detec-
tor. Data were collected and processed using System Gold software
(Beckman Instruments Inc.).
2.6. Analysis of Ca2 +- and phospholipid-binding properties
The Ca2-binding properties of recombinant proteins were inferred
by the decrease in intrinsic tryptophan £uorescence [22,23]. The pro-
tein sample (2 ml, 10 Wg/ml in 20 mM HEPES bu¡er, pH 7.4 con-
taining 150 mM NaCl) was stirred in a thermostated (25‡C) quartz
cuvette in the Luminescence Spectrometer. Excitation was at 280 nm
and intrinsic £uorescence was monitored continuously at 300 to 400
nm, with excitation and emission band widths of 5 and 15 nm respec-
tively, and with a 290 nm cut-o¡ ¢lter for the emission beam. An
aliquot (10 Wl) of 1 M CaCl2 was added, and the decrease in £uores-
cence was monitored over the emission bands. The ratio of the mag-
nitude of the decrement (vI340) over the initial £uorescence (Io340) of
the recombinant proteins was extrapolated and compared to that
obtained for plasma prothrombin.
The phospholipid-binding properties of the proteins were moni-
tored by right angle light scattering [24,25]. Phospholipid vesicles
(phosphatidyl choline-phosphatidyl serine, 75:25 mol:mol) were pre-
pared (10 Wg/ml in 20 mM Tris-HCl bu¡er, pH 7.4 containing 150
mM NaCl [26]), and an aliquot (2 ml) was stirred in a quartz cuvette
at 25‡C in the Luminescence Spectrometer. The right angle scattering
intensity was monitored continuously over 10 min with an excitation
wavelength of 400 nm and an emission wavelength of 410 nm, both
with a 2.5 nm slit width. An aliquot of protein was added to give a
¢nal concentration of 20 Wg/ml. After stirring for a further 5 min., an
aliquot (10 Wl) of 1 M CaCl2 was added, inducing the calcium-depend-
ent protein-phospholipid interaction. Data were collected at intervals
of 1 s, and the increase in light scattering was monitored for 5 min or
until a stable reading was obtained.
2.7. Coagulation assays
Coagulation assays were performed with recombinant prothrombin
and variants using human-prothrombin de¢cient plasma under con-
ditions recommended by the manufacturer (Sigma Diagnostic, St.
Louis, MO, USA).
3. Results
3.1. Gla analysis of human prothrombin
Previously, we have shown that CE-LIF analysis of Gla is
rapid, reproducible and sensitive with a limit of detection for
FTC-Gla of 5.0U10311 M [16]. Initially, the assay was used to
detect Gla in commercial preparations of plasma prothrom-
bin, plasma factor X and osteocalcin that had been hydro-
lyzed with base, as well as to detect Gla directly in plasma and
urine [16]. To assess the carboxylation status of prothrombin
expressed using the pNUT-BHK system [18], samples of hu-
man plasma prothrombin (phFII) and recombinant human
prothrombin (rhFII) were hydrolyzed, derivatized with
FITC and the FTC-labeled acidic amino acids were analyzed
by CE-LIF. As a control, the non-Gla-containing ferric iron-
binding protein from N. gonnhoreae was also analyzed. Fig. 1
shows the results of CE-LIF analyses of both acid and base
hydrolysates of rhFII. The expected FTC-Gla peak was ob-
served in the alkaline hydrolysate of rhFII (panel C); how-
ever, no FTC-Gla peak was observed in the acid-hydrolyzed
samples of rhFII (panel B) nor in the base-hydrolyzed sample
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of ferric iron-binding protein (panel A). In addition, the FTC-
Glu to FTC-Asp ratio of the acid-hydrolyzed sample of rhFII
was slightly higher than that of the base-hydrolyzed sample.
These results are consistent with the decarboxylation of Gla to
Glu during the acid hydrolysis step. In some electrophero-
grams, an unidenti¢ed peak appeared that eluted between
the FTC-Asp and FTC-Gla peaks; however, this peak did
not interfere with the quanti¢cation of the three acidic amino
acids of interest. The prothrombin analysis shown in Fig. 1
represents the hydrolysis of 1 Wg of protein followed by a 400-
fold dilution of the FTC-labeled hydrolysate prior to CE-LIF.
Thus, nanogram quantities of protein are required for the Gla
analysis making this CE-LIF method the most sensitive assay
for Gla analysis reported to date. A sample of rhFII was then
analyzed for Gla content, as shown in Fig. 2 (panel B). As
summarized in Table 1, both the phFII and rhFII samples
had Gla/Glu ratios corresponding to the ten residues of Gla
per molecule of protein [27,28]. The high Gla content is con-
sistent with the puri¢cation of rhFII by pseudo-a⁄nity chro-
matography using calcium gradients; this method was devel-
oped to enrich for fully carboxylated species of recombinant
human protein C [21].
3.2. Gla analysis of mutated forms of recombinant human
prothrombin
Samples of two mutant forms of human prothrombin were
then investigated. A chimeric protein was prepared in which
the second kringle of human prothrombin was replaced with
the equivalent region of bovine prothrombin; the mutant
form was designated rhBK2. After expression in BHK cells,
rhBK2 was puri¢ed in the same way as rhFII. During the
pseudo-a⁄nity chromatography step, rhBK2 eluted as two
populations (designated rhBK2A and rhBK2B) eluting at 10
mM CaCl2 and 17.5 mM CaCl2, respectively. These results
suggest that the two sub-populations of rhBK2 have di¡erent
a⁄nities for Ca2 that re£ect the presence or absence of the
Ca2-dependent conformational change. The Gla content of
the two sub-populations were then determined (Fig. 2, panels
C and D). As shown in Table 1, rhBK2A and rhBK2B con-
tain 8.6 þ 0.1 and 6.2 þ 0.7 residues of Gla, respectively.
3.3. Calcium- and phospholipid-binding properties
To correlate the Gla content with the Ca2-induced confor-
mational change, the calcium-binding and phospholipid-bind-
ing properties of rhBK2A and rhBK2B were assessed by using
intrinsic tryptophan £uorescence and right angle light scatter-
ing, respectively. The results were compared with those ob-
tained with phFII and rhFII. The results of tryptophan £uo-
rescence quenching on calcium binding are shown in Fig. 3A.
The rhFII and rhBK2A showed very similar tryptophan £uo-
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Fig. 1. Electropherograms from hydrolysates of recombinant human
prothrombin analyzed by CE-LIF. Panel A: Alkaline hydrolysis of
ferric iron-binding protein. Panel B: Acid hydrolysis of rhFII. Panel
C: Base hydrolysis of rhFII. The peaks corresponding to the FTC-
labeled acidic amino acids were determined from their migration
times; where necessary, the identity of the FTC-Gla peak was con-
¢rmed by adding an aliquot of standard FTC-Gla to the sample,
and repeating the CE-LIF analysis. The peaks corresponding to
FTC-Glu (1), FTC-Asp (2) and FTC-Gla (3) are labeled.
Fig. 2. Electropherograms from alkaline hydrolysates of prothrom-
bin variants analyzed by CE-LIF. Panel A: phFII. Panel B: rhFII.
Panel C: rhBK2A. Panel D: rhBK2B. The peaks corresponding to
FTC-Glu (1), FTC-Asp (2) and FTC-Gla (3) are labeled.
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rescence quenching responses that were similar to those ob-
served for phFII. These results suggest that the proteins
undergo a similar conformational change upon calcium bind-
ing. Consistent with a lower Gla content, rhBK2B exhibited a
slightly smaller response on the addition of calcium (Fig. 3A).
In the right angle light scattering experiments, the addition
of calcium to the suspension of protein and phospholipid
vesicles promotes the formation of protein-lipid interactions
resulting in increased light scattering intensity as the e¡ective
radius of the phospholipid vesicles increases. Fig. 3B shows
the increment in right angle light scattering of the protein
samples upon addition of Ca2, monitored over a time course
of 10 min. On addition of Ca2, all the recombinant proteins
showed diminished binding to phospholipid compared to the
phFII (Table 1). The relative response in right angle light
scattering of rhFII was 54% compared to phFII. The rhBK2A
protein had a lesser response (44%) while the rhBK2B protein
(with the least Gla residues) had only a 24% response relative
to phFII (Table 1). Thus, the number of Gla residues corre-
lates with the ability of prothrombin to bind to phospholipid
vesicles. These results indicate that the phospholipid-binding
property of rhBK2B was severely a¡ected when the Gla con-
tent was reduced to an average of approximately six residues.
3.4. Clotting activities
To correlate these binding studies with biological activity,
clotting assays were performed on phFII and the recombinant
molecules (Table 1). As reported previously [18], rhFII has
only 62% of the clotting activity of phFII. The mutant
rhBK2A has a similar clotting activity to rhFII (Table 1),
suggesting that the point mutations introduced with the bo-
vine kringle 2 region do not a¡ect the assembly and activity of
the prothrombinase complex under the conditions used. In
contrast, the mutant rhBK2B had only 9% of the clotting
activity of phFII (Table 1). Thus, the V6 residues of Gla in
rhBK2B are insu⁄cient for the function of prothrombin in the
prothrombinase complex.
4. Discussion
A variety of di¡erent expression systems have been used to
express recombinant vitamin K-dependent clotting factors in-
cluding prothrombin, factor X, factor IX, factor VII and pro-
tein C [29]. Although prothrombin has been expressed at low
yields in a fully carboxylated form [30], increasing the yield of
recombinant protein is associated with the appearance of par-
tially carboxylated forms [18,30]. It has been proposed that
high levels of recombinant protein overwhelm the vitamin K-
dependent carboxylation capacity of the tissue culture cell
lines [30]. As originally described for plasma-derived pro-
thrombin, there is an abrupt loss of functional activity asso-
ciated with the loss of as few as three of the ten Gla residues
found in the plasma protein [31]. Further studies showed that
most if not all of the Gla residues are required for complete
prothrombin function [32] with Gla-16, Gla-25 and/or Gla-26
being involved in the formation of a critical high a⁄nity met-
al-binding site [33]. A second high a⁄nity metal-binding site
appears to be comprised of Gla-6, Gla-14, Gla-19 and Gla-20
[33]. Similar studies with recombinant proteins have revealed
Gla residues in protein C that are critical for its anti-coagu-
lant activity [34] and calcium- and phospholipid-binding prop-
erties [35]. To enrich for fully carboxylated species, puri¢ca-
tion techniques have been developed such as a⁄nity
chromatography using conformation-dependent antibodies
[30,36] and pseudo-a⁄nity chromatography with calcium gra-
dients [21].
In this study, the Gla contents of phFII and rhFII have
been measured directly. Consistent with previous studies
[18], the rhFII produced in the pNUT-BHK cell system has
a lower clotting activity than phFII. As the rhFII is fully
carboxylated (Table 1), the reason for this reduction in activ-
ity is unclear as the only potential di¡erence between phFII
and rhFII is heterogeneous post-translational modi¢cation
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Fig. 3. Calcium-binding and phospholipid-binding properties of pro-
thrombin variants. Panel A: The relative change in intrinsic trypto-
phan £uorescence after calcium addition. Panel B: The relative
change in light scattering on calcium-dependent binding to phospho-
lipid vesicles. Each experiment represents the average of three inde-
pendent measurements, and the bars represent the standard devia-
tion. phFII, plasma-derived prothrombin; rhFII, recombinant
prothrombin; rhBK2A, Gla-rich prothrombin variant with bovine
kringle 2; rhBK2B, Gla-poor prothrombin variant with bovine krin-
gle 2.
Table 1
Correlation of Gla content and biological activities of various species of human prothrombin
Protein Gla/Glu ratio Gla
content1
vI/Io Trp
(320 nm)
Relative Ca2
binding (%)
vI/Io
(410 nm)
Relative PL
binding (%)
Clotting
time (s)
Relative clotting
time (%)
phFII 0.07377 þ 0.0002 10 þ 0.3 10.25 þ 0.05 100 0.25 þ 0.03 100 20.7 þ 0.6 100
rhFII 0.07371 þ 0.0013 10 þ 0.2 9.10 þ 0.10 89 þ 1 0.13 þ 0.02 53 þ 6 25.3 þ 0.6 62 þ 3
rhBK2A 0.06366 þ 0.0008 8.6 þ 0.1 9.75 þ 0.35 95 þ 3 0.11 þ 0.01 43 þ 1 25.4 þ 0.5 62 þ 3
rhBK2B 0.04584 þ 0.0052 6.2 þ 0.7 8.70 þ 0.10 85 þ 1 0.06 þ 0.01 24 þ 2 61.0 þ 1.0 8.8 þ 0.3
1Residues per mol protein.
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(such as glycosylation or incomplete propeptide removal) of
the recombinant protein. A variant of rhFII (rhBK2) was also
expressed in BHK cells at high levels ; this variant had the
second cringle domain of human prothrombin replaced by
its bovine counterpart. During the puri¢cation of rhBK2 by
pseudo-a⁄nity chromatography, a Gla-rich component was
separated from a Gla-poor component. Direct Gla analysis
of these sub-populations revealed the presence of 8.6 and
6.2 residues of Gla per molecule of rhBK2A and rhBK2B,
respectively. While both species bound Ca2, only the Gla-
rich species bound signi¢cantly to phospholipid vesicles, and
was active in a clotting assay (Table 1). Thus, the direct meas-
urement of Gla content in the recombinant proteins correlates
well with clotting activity.
CE-LIF is the method of choice for the analysis of small
amounts of amino acids and peptides [37]. The small sample
size and speed of analysis are well suited to the assessment of
the carboxylation status of recombinant vitamin K-dependent
proteins. Potentially, the CE-LIF-based Gla analysis used in
this paper could be used for a protein sample from a partially
puri¢ed source such as a band from an SDS-polyacrylamide
gel. The detection limit for the CE-LIF assay for Gla is well
below the detection limit for chromogenic strains. Thus, for
some applications, the long sample puri¢cation and prepara-
tion time could be avoided.
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